Elisa Castillo

Ms. Elisa Castillo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
CLCarlos Lahoz
Carlos Lahoz
ECElisa Castillo
Elisa Castillo
JMJose Maria Mostaza
Jose Maria Mostaza
ODOlaya De Dios
Olaya De Dios
MSMiguel A. Salinero-Fort
Miguel A. Salinero-Fort
OGOn behalf of the Investigators of the SPREDIA-2 Group
On behalf of the Investigators of the SPREDIA-2 Group
Background: Adherence to a Mediterranean diet seems to be inversely associated with C-reactive protein (CRP) concentration. A 14-point Mediterranean Diet Adherence Screener (MEDAS) has been developed to assess dietary compliance. Objective: The aim of this study was to assess whether each of the MEDAS questions as well as their final score were associated with the levels of CRP in general Spanish population. Methods: Cross-sectional analysis of 1411 subjects (mean age 61 years, 43.0% males) randomly selected from the general population. CRP levels were determined by a commercial ELISA kit. Adherence to the Mediterranean diet was measured by the 14-point MEDAS. Results: There was an inverse correlation between adherence to the Mediterranean diet and the CRP concentration, even after adjusting by age, gender, hypertension, metabolic syndrome, body mass index, statin treatment and hypertension treatment (p = 0.041). Subjects who consume ≥2 servings of vegetables per day (p = 0.003), ≥3 pieces of fruit per day (p = 0.003), ≥1 serving of butter, margarine, or cream per day (p = 0.041) or ≥3 servings of fish/seafood per week (p = 0.058) had significantly lower levels of CRP. Conclusions: Adherence to a Mediterranean-type diet measured by a simple questionnaire is associated with lower CRP concentration. However, this association seems to be particularly related to a higher consumption of vegetables, fruits, dairy products, and fish.

1 July 2018 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
JMJose Maria Mostaza
Jose Maria Mostaza
CLCarlos Lahoz
Carlos Lahoz
MSMiguel A. Salinero-Fort
Miguel A. Salinero-Fort
ODOlaya De Dios
Olaya De Dios
ECElisa Castillo
Elisa Castillo
MPMargarita Ruiz Pacheco
Margarita Ruiz Pacheco

5 October 2024 in JHEP Reports
Verified
Journal Article
Open access
RSRubén Sánchez-Aldehuelo
Rubén Sánchez-Aldehuelo
CVCàndid Villanueva
Càndid Villanueva
JGJoan Genescà
Joan Genescà
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
ECElisa Castillo
Elisa Castillo
AAAgustín Albillos
Agustín Albillos
Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and their dynamics in relation to the first decompensation. This study is nested within the PREDESCI trial, which investigated non-selective beta-blockers for preventing decompensation in compensated cirrhosis and clinically significant portal hypertension (CSPH: hepatic venous pressure gradient ≥10 mmHg). Blood biomarkers were measured at baseline and at 1 and 2 years in patients who remained compensated and had available samples (n = 164). Values of patients with CSPH were split at each time point by decompensation development in the next time interval after sampling. We also included 54 patients with cirrhosis and subclinical portal hypertension (PH) and 35 controls. We assessed markers of inflammation (interleukin-6 [IL-6], tumor necrosis factor-alpha, von Willebrand factor [vWF], C-reactive protein), macrophage activation (CD14, CD163), intestinal barrier integrity (fatty acid-binding protein [FABP], haptoglobin), and bacterial translocation (lipopolysaccharide [LPS]). IL-6, CD163, and vWF were higher (p <0.01) at baseline in patients with cirrhosis and CSPH compared to those with subclinical PH and controls. IL-6 increased (p <0.05) at 1 year in patients with CSPH, with a greater rise in those who developed decompensation. CD163 was higher (p <0.01) in patients who decompensated at baseline and 1 and 2 years. FABP was elevated (p <0.01) in patients with CSPH compared to subclinical PH and controls at baseline and 1 year, while haptoglobin was lower (p <0.01). LPS was higher (p <0.01) in patients with CSPH than in those with subclinical PH and controls and increased at 1 year regardless of decompensation development. Inflammation and bacterial products are present in the systemic circulation in patients with compensated cirrhosis and CSPH. Progressive inflammation precedes the first decompensation. Systemic inflammation drives cirrhosis progression during the decompensated stage, but its role in the compensated stage is unclear. We evaluated biomarkers of systemic inflammation, intestinal barrier integrity and bacterial translocation in patients with compensated cirrhosis and their dynamics in relation to the first decompensation. We demonstrate that low-grade inflammation and bacterial products are present in the systemic circulation in compensated cirrhosis, provided clinically significant portal hypertension has developed. We also show that worsening of systemic inflammation precedes the development of first clinical decompensation.

28 July 2026 in Journal of Hepatology
Verified
Journal Article
Open access
ECElisa Castillo
Elisa Castillo
MFMarco Felber
Marco Felber
LPLorena Paule
Lorena Paule
OJOriol Juanola
Oriol Juanola
LWLorena Wyss
Lorena Wyss
RWReiner Wiest
Reiner Wiest